A Plasmonic "Lid-Off" Nanoplatform for Spatiotemporally Controlled PA/NIR-II Dual-Modal Imaging and Cuproptosis-Based Synergistic Photothermal and Chemodynamic Therapy.

Current nanotheranostics are plagued by non-target drug release and uncontrolled activation which compromise imaging fidelity and therapeutic precision. Herein, we report an origin-regenerated Cu9S8@CH1055@Cu9S8 nanocapsules (CCC NCs) that unlocks dual-modal imaging-guided trimodal therapy via a light-triggered "lid-off" mechanism. The dense outer Cu9S8 shell tightly encapsulates the NIR-II dye CH1055, ensuring its dormant state during systemic circulation. Upon the 1064 nm laser irradiation, localized surface plasmon resonance (LSPR) induces rapid photothermal disruption of the lid, thereby achieving a light-gated "lid-off" effect. This effect synchronously enables high-contrast NIR-II fluorescence/photoacoustic dual-modal imaging and initiates on-demand trimodal therapy integrating photothermal ablation, chemodynamic therapy, and cuproptosis. The single near infrared wavelength-triggered design achieves remarkable suppression of Mouse prostate carcinoma (RM-1) prostate tumor progression with no detectable systemic toxicity. Thereby, our work establishes the "lid-off" nanoarchitecture as a robust platform for spatiotemporally precise, imaging-guided multimodal cancer theranostics.